Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Soleno Therapeutics, Inc. (SLNO) had Income from Continuous Operations of $26.01M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$66.02M |
|
$26.01M |
|
$1.14M |
|
$64.88M |
|
$43.91M |
|
$22.11M |
|
$3.91M |
|
$26.01M |
|
$26.01M |
|
$26.01M |
|
|
Income from Continuous Operations |
$26.01M |
$26.01M |
|
$26.01M |
|
$22.11M |
|
$22.62M |
|
53.33M |
|
54.92M |
|
$0.49 |
|
$0.47 |
|
| Balance Sheet Financials | |
$534.85M |
|
$0.15M |
|
$65.04M |
|
$599.89M |
|
$33.25M |
|
$49.85M |
|
$71.84M |
|
$105.09M |
|
$494.81M |
|
$489.46M |
|
$494.81M |
|
53.70M |
|
| Cash Flow Statement Financials | |
$-1.91M |
|
$-76.42M |
|
$237.06M |
|
$87.93M |
|
$246.66M |
|
$158.73M |
|
$34.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.08 |
|
-- |
|
-- |
|
0.09 |
|
0.10 |
|
98.27% |
|
33.48% |
|
33.48% |
|
-- |
|
39.40% |
|
39.40% |
|
$-1.92M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.17 |
|
2.59 |
|
34.77 |
|
5.26% |
|
5.31% |
|
4.34% |
|
4.78% |
|
$9.21 |
|
$-0.04 |
|
$-0.03 |
|